Antibodies

Earn $5,400 And Help Combat Malaria: Bill Gates Foundation-Supported Human Trial Awaits Those Brave Enough To Allow Deliberate Infection

FDA Rescinds Authorization For Regeneron, Eli Lilly COVID-19 Antibody Treatments: Here's Why

Regeneron Antibody Treatment Cuts Risk Of Death In Some Critical COVID-19 Patients, Large-Scale Study Finds

FDA Rescinds Authorization For Regeneron, Eli Lilly COVID-19 Antibody Treatments: Here's Why

Regeneron Antibody Treatment Cuts Risk Of Death In Some Critical COVID-19 Patients, Large-Scale Study Finds

Eli Lilly Antibody Drug Combo For COVID-19 Gets FDA Emergency Approval

Regeneron To Supply US With Another 1.25M COVID-19 Treatment Doses

Eli Lilly Antibody Drug Combo For COVID-19 Gets FDA Emergency Approval

Regeneron To Supply US With Another 1.25M COVID-19 Treatment Doses

Regeneron COVID-19 Antibody Cocktail Shows Positive Response In Hospitalized Patients

Eli Lilly's Antibody Treatment For COVID-19 Gets FDA Emergency Use Authorization

Antibodies Recent News

Regeneron Says COVID-19 Antibody Cocktail Reduced Viral Load, Need For Medical Care In Late-Stage Trial

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) said Wednesday data from late-stage clinical trials is indicative that its antibody cocktail for COVID-19 both reduced viral load and need for medical attention.

Trump Touts Regeneron Antibody Cocktail As Cure, 'I Felt Good Immediately'

President Donald Trump touted Regeneron Pharmaceuticals Inc’s (NASDAQ: REGN) antibody cocktail as a "cure" for COVID-19 in a video shared after his return to the Oval Office on Wednesday.

Bill Gates Says Regulatory Approval For Antibody Drugs Could Sharply Reduce COVID-19 Mortality

Antibody drugs currently undergoing testing could be a panacea for the COVID-19 pandemic ravaging the world once they get regulatory approval, according to the founder of Microsoft Corporation (NASDAQ: MSFT) Bill Gates.

Regeneron Says COVID-19 Antibody Cocktail Helped Non-Hospitalized Patients Heal Faster In Early Trials

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) announced Tuesday that its antibody cocktail drug showed positive effects in non-hospitalized COVID-19 patients.

Regeneron Says Its Coronavirus Antibody Cocktail Shows Promise For Both Prevention, Treatment In Animal Testing

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) said Monday that a non-peer-reviewed study indicated its antibody drug combination both prevented and treated COVID-19 in animals, as earlier

Introduction to Monoclonal Antibodies for Cancer Therapy